NCT01324492View on ClinicalTrials.gov

Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Lung Neuroendocrine Neoplasm
Interventions
DRUG

RAD001

Trial Locations (4)

100730

Novartis Investigative Site, Beijing

510030

Novartis Investigative Site, Guangzhou

Unknown

Novartis Investigative Site, Changchun

Novartis Investigative Site, Shenyang

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY